3 Results for "

bEnd.3 mouse brain endothelial cells

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "bEnd.3 mouse brain endothelial cells" in MCE Product Catalog:

Cat. No.: HY-124314
CAS No.: 1620582-23-1
Target:  

MAGL DAGL

Research Areas:  

Metabolic Disease

LEI-106 is a dual ABHD6 and DAGL-α inhibitor, with a Ki of 0.8 μM for ABHD6, and an IC50 of 18 nM and a Ki of 0.7 μM for DAGL-α. LEI-106 blocks the synthesis of 2-arachidonoylglycerol, reduces the level of endothelial cell-derived 2-arachidonoylglycerol, without altering the levels of cannabinoids and diacylglycerol. LEI-106 is applicable to research related to diet-induced obesity and metabolic syndrome .
loading...
    loading...
Cat. No.: HY-P11918
CAS No.: 2350190-98-4
Target:  

Transferrin Receptor

Research Areas:  

Neurological Disease

D-T7 is a transferrin receptor (TfR) binding peptide that mediates brain-targeted delivery. D-T7 acts as a penetration enhancer and uptake promoter for nanoparticles in glioma tissues and target cells. D-T7 can be used in glioma research .
loading...
    loading...
Cat. No.: HY-P992126
CAS No.: 3059389-31-7
Synonyms: EYE-103; MK-3000
Target:  

Wnt

Research Areas:  

Neurological Disease

Remigromig (EYE-103; MK-3000) is a humanized dual-target monoclonal antibody that targets LRP5 and FZD4. Remigromig activates the Wnt/β-catenin signaling pathway by mimicking the natural ligand Norrin, induces tight junction formation and restores blood-retinal barrier function. Administered via intravitreal injection, Remigromig reduces retinal vascular leakage, and demonstrates improvements in best-corrected visual acuity and reductions in retinal thickness in studies of diabetic macular edema. Remigromig can be used for research related to macular degeneration .
loading...
    loading...